Data Sheet (Cat.No.TMPY-07100)

TargetMol

A2AR Protein-VLP, Human, Recombinant (Flag)

General Information

Protein Construction:	A DNA sequence encoding the Human AA2AR (P29274) (Met1-Ser412) was expressed with a flag tag at the N-terminus.
Species:	Human
Expression Host:	HEK293 Cells
Accession:	P29274
Molecular Weight:	38.06 kDa (predicted)

QC Testing

Biological Activity:	Immobilized A2AR Protein-VLP, Human, Recombinant (Flag) (Cat#TMPY-07100) at 5 μg/mL (100 μL/well) can bind Anti-Human ADORA2A Monoclonal antibody, Mouse IgG2a, the EC50 is 5-20 ng/mL.
Endotoxin:	< 1.0 EU per μg of the protein as determined by the LAL method
Formulation:	Supplied as sterile 50 mM Hepes, 150 mM NaCl, 10% Trehalose, pH 7.2. Please contact us for any concerns or special requirements. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Preparation and Storage

Stability & Storage:

Samples are stable for up to twelve months from date of receipt at -70℃. Store it under sterile conditions at -70℃ or lower. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Shipping:

Shipping with blue ice.

Protein Background

Adenosine Receptor Subtype A2a (A2aR) is a G-protein coupled receptor that mediates adenosine (a potent immunosuppressor) signaling in leukocytes. A2aR has been implicated in neuroinflammation and synaptic plasticity-related processes. Signaling through A2aRs inhibits local and systemic inflammation and A2aR expression showed protective effects against non-alcoholic steatohepatitis (NASH) in the liver. A2aR deficiency triggers spontaneous inflammation and NASH-Hepatocellular Carcinoma (HCC) in mice while low A2aR gene expression in human HCC is associated with hepatic inflammation and poor survival. Reducing adenosine signaling via A2aR antagonism provides an alternative targeted strategy to modulate the number and efficacy of infiltrating effector T cells within the immunosuppressive tumor microenvironment. Co-blockade of A2aR signaling and CD73 reduced tumor initiation, growth, and metastasis.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481